Cargando…

Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?

Detalles Bibliográficos
Autores principales:	Prasad, Rajendra, Singh, Abhijeet, Gupta, Nikhil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tuberculosis Association of India. Published by Elsevier B.V. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221684/ https://www.ncbi.nlm.nih.gov/pubmed/36460365 http://dx.doi.org/10.1016/j.ijtb.2022.06.006

Ejemplares similares

Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope
por: Prasad, Rajendra, et al.
Publicado: (2017)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Detect–Treat–Prevent–Build: Strategy for TB Elimination in India by 2025
por: Purty, Anil Jacob
Publicado: (2018)

Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone
por: Singh, Pravin K., et al.
Publicado: (2019)

High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal
por: Koirala, S., et al.
Publicado: (2021)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Prospective study on outcome of MDR-TB using the shorter regimen during COVID-19 pandemic
por: Kumar, G Sravan, et al.
Publicado: (2023)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

2025 too short time to eliminate tuberculosis from India
por: Prasad, Rajendra, et al.
Publicado: (2017)

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

TB control in India in the COVID era
por: Behera, D.
Publicado: (2021)

Cost of digital technologies and family-observed DOT for a shorter MDR-TB regimen: a modelling study in Ethiopia, India and Uganda
por: Rosu, Laura, et al.
Publicado: (2023)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

A world of cities and the end of TB
por: Prasad, Amit, et al.
Publicado: (2016)

Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome
por: Prasad, Rajendra, et al.
Publicado: (2017)

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

Experience of “One Stop TB Diagnostic Solution” Model in Engaging a Private Laboratory for End-to-End Diagnostic Services in the National TB Elimination Program in Hisar, India
por: Raju, Rajesh, et al.
Publicado: (2023)

Confronting TB/HIV in the era of increasing anti-TB drug resistance
por: Chakaya, Jeremiah, et al.
Publicado: (2008)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study
por: Hassane-Harouna, Souleymane, et al.
Publicado: (2020)

Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2022)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

TB vaccine development and the End TB Strategy: importance and current status
por: Fletcher, Helen A., et al.
Publicado: (2016)

The End TB Strategy: India can blaze the trail
por: Pai, Madhukar
Publicado: (2015)

Engaging private pharmacies to help end TB in India
por: Gandhi, R., et al.
Publicado: (2022)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Ending the TB pandemic: the urgency of a new and improved TB vaccine and the World Health Organization's TB Vaccine Accelerator Council
por: Adepoju, Victor Abiola, et al.
Publicado: (2023)

Ending TB: the world’s oldest pandemic
por: Kim, Peter S, et al.
Publicado: (2021)

Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy
por: Beltran, Caroline G. G., et al.
Publicado: (2020)

Community-based TB testing as an essential part of TB recovery plans in the COVID-19 era
por: Zokufa, N., et al.
Publicado: (2021)

The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals
por: Lönnroth, Knut, et al.
Publicado: (2016)

How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India?
por: Burugina Nagaraja, Sharath, et al.
Publicado: (2011)

Pediatric TB detection in the era of COVID-19
por: Golandaj, Javeed A.
Publicado: (2022)

MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic
por: Gonzalo-Asensio, Jesus, et al.
Publicado: (2017)

The TAM-TB Assay—A Promising TB Immune-Diagnostic Test With a Potential for Treatment Monitoring
por: Ahmed, Mohamed I. M., et al.
Publicado: (2019)

TB Anywhere is TB Everywhere
por: Wortham, Jonathan M.
Publicado: (2018)

TB or not TB! That’s the question
por: Nugud, Ahmed, et al.
Publicado: (2019)

A rare case of sarcoidosis with necrotizing mediastinal lymphadenitis misdiagnosed as multidrug-resistant tuberculosis (MDR- TB)
por: Prasad, Rajendra, et al.
Publicado: (2022)

Capturing patient-reported and quality of life outcomes with use of shorter regimens for drug-resistant tuberculosis: mixed-methods substudy protocol, TB PRACTECAL-PRO
por: Stringer, Beverley, et al.
Publicado: (2021)

Diagnosis: Reactivation of pulmonary TB
por: Takhar, Rajendra, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_97ivohre4ge6mkra5darfu8k3a